TARSUS PHARMACEUTICALS, INC. — Earnings
Most recent reported period: FY2025 (Q4) (filed for period ending 2025-12-31) · sourced from SEC EDGAR
Next earnings (estimated): Wed, April 1, 2026 — 29 days overdue (likely already filed but EDGAR cache cold). Anchored to latest quarter-end + 91 days. Analyst-confirmed dates land in a follow-up wave.
YoY = vs same quarter prior year (seasonality-adjusted)
Recent earnings · last 8 quarters
| Quarter end | Revenue | YoY | Net Income | YoY | Op. Margin |
|---|---|---|---|---|---|
| 2025-12-31 | $152M | ↑+128.4% | — | — | — |
| 2025-09-30 | $119M | ↑+146.7% | $-13M | ↑+46.3% | -12.2% |
| 2025-06-30 | $103M | ↑+151.5% | $-20M | ↑+38.9% | -21.6% |
| 2025-03-31 | $78M | ↑+183.7% | $-25M | ↑+29.7% | -33.5% |
| 2024-12-31 | $66M | ↑+407.9% | — | — | — |
| 2024-09-30 | $48M | ↑+2471.8% | $-23M | ↑+40.2% | -52.3% |
| 2024-06-30 | $41M | — | $-33M | ↓-5.9% | -81.6% |
| 2024-03-31 | $28M | ↑+1004.6% | $-36M | ↓-52.6% | -136.5% |
Analyst consensus estimates (EPS / Revenue) and implied move from options will land in a follow-up wave. For now, YoY-vs-prior-year-quarter is the surprise proxy.
Last earnings · FY2025 (Q4)
Revenue
$152M
↑+128.4% +$85M YoY
Earnings surprise · last 8 quarters
YoY % change · proxy for analyst surprise until estimates landEPS history · last 10 fiscal years
diluted, GAAP, annualNote: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.
Go deeper
TARS Sankey — flow of dollars
See how revenue waterfalls through every line item to net income for the latest reported quarter, with prior-period comparison.
Open SankeyTARS Key Metrics — EPS, ROE, ROIC
10 CFA-grade fundamental ratios — EPS, BVPS, ROE, ROA, ROIC, Debt/Equity, Current Ratio. Compare across years.
Open Key Metrics